The mutational profile of KRAS, NRAS and Harvey rat sarcoma viral oncogene homolog (HRAS) were also recently analyzed in large patient cohorts, pointing to novel associations connecting age, gender and tumor subsite with specific mutations that could be potentially exploited for therapeutic purposes [62]. This evidence concerns the gene HRAS and neoplasm.